Literature DB >> 32116060

The latest advances of cisplatin liposomal formulations: essentials for preparation and analysis.

Fahimeh Zahednezhad1, Parvin Zakeri-Milani2, Javid Shahbazi Mojarrad3, Hadi Valizadeh4.   

Abstract

Introduction: Cisplatin has been indicated for several malignancies all over the world for many years. Increasing patient tolerance for high dose of chemotherapeutics and reducing side effects has been granted by drug encapsulated liposomal systems. There have been much efforts for improving cisplatin delivery to the site of action via liposomes both in research and clinical trials such as SPI-077®, Liplacis®, and Lipoplatin®.Areas covered: In this review, we have discussed about cisplatin and its liposomal formulations, focusing on different preparation methods and analysis approaches such as atomic absorption, mass spectroscopy, UV, electrochemical methods, and emphasizing on HPLC as one of the accurate and specific methods for determination of cisplatin species and also measurement of total platinum by derivation.Expert opinion: Liposome of cisplatin has offered potential beneficial aspects over cisplatin formulation. However, there are several challenges in preparing and analysis of cisplatin liposomes due to cisplatin's great reactivity, formation of several species, high affinity to bioelements, insufficient release at the tumor site, and inefficient loading. Cisplatin resistance is another challenge which should be prevented by higher loading capacity. Charge-dependent interactions should also be highly considered especially in the preparation step.

Entities:  

Keywords:  Analysis; HPLC; cisplatin; derivation; liposome; preparation methods

Mesh:

Substances:

Year:  2020        PMID: 32116060     DOI: 10.1080/17425247.2020.1737672

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  7 in total

Review 1.  Advances in Delivery of Chemotherapeutic Agents for Cancer Treatment.

Authors:  Asmita Yadav; Sakshi Singh; Harmik Sohi; Shweta Dang
Journal:  AAPS PharmSciTech       Date:  2021-12-14       Impact factor: 3.246

2.  Nanoparticles of cisplatin augment drug accumulations and inhibit multidrug resistance transporters in human glioblastoma cells.

Authors:  Naseer Maliyakkal; Asmy Appadath Beeran; Nayanabhirama Udupa
Journal:  Saudi Pharm J       Date:  2021-07-15       Impact factor: 4.330

3.  Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer.

Authors:  Shuhang Wang; Jingxin Gou; Yue Wang; Xinyi Tan; Linxuan Zhao; Xiangqun Jin; Xing Tang
Journal:  Int J Nanomedicine       Date:  2021-03-22

4.  MiR-874-3p represses the migration and invasion yet promotes the apoptosis and cisplatin sensitivity via being sponged by long intergenic non-coding RNA 00922 (LINC00922) and targeting Glycerophosphodiester Phosphodiesterase Domain Containing 5 (GDPD5) in gastric cancer cells.

Authors:  Xiaoyu Zhang; Xudong Dai; Xin Zhao; Jian Wang; Jin Dou; Haiwen Zhuang; Ning Chen; Haijian Zhao
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

Review 5.  Stimuli-Responsive Drug Delivery Systems for the Diagnosis and Therapy of Lung Cancer.

Authors:  Xu Lin; Jiahe Wu; Yupeng Liu; Nengming Lin; Jian Hu; Bo Zhang
Journal:  Molecules       Date:  2022-01-30       Impact factor: 4.411

6.  Comparison of Cytotoxic and Ototoxic Effects of Lipoplatin and Cisplatin in Neuroblastoma In Vivo Tumor Model.

Authors:  Hande Evin Eskicioğlu; Yüksel Olgun; Tekincan Çağrı Aktaş; Safiye Aktas; Efsun Kolatan; Efe Serinan; Zekiye Altun; Günay Kırkım; Osman Yılmaz; Nur Olgun
Journal:  J Int Adv Otol       Date:  2022-09       Impact factor: 1.316

Review 7.  Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas.

Authors:  Jaewan Jeon; Sungmin Lee; Hyunwoo Kim; Hyunkoo Kang; HyeSook Youn; Sunmi Jo; BuHyun Youn; Hae Yu Kim
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.